NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 53.98

-6.5%

Nov 13 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	9/28/2006 8:52:30 PM
	Read Replies (1) of 507

Is the analyst distinguishing between introduction and rollout? or is something else at play here???? Nektar Therapeutics upgraded to "outperform" Thursday, September 28, 2006 7:50:05 AM ET Miller Johnson Steichen Kin. NEW YORK, September 28 (newratings.com) - Analyst Carl Byrnes of Miller Johnson Steichen Kinnard upgrades Nektar Therapeutics (NKTR.NAS) from "market perform" to "outperform." The target price is set to $18. In a research note published this morning, the analyst mentions that the recent decline in the company's share price is likely to have been overdone. The full roll-out of Exubera in February 2007 is expected to be accompanied by a significant rise in available inventory and an extensive marketing programme, the analyst adds. Miller Johnson Steichen Kinnard believes that there is significant pent-up demand for the drug in the unsuccessful oral regimens.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next